同时，口服VK2735还表现出令人鼓舞的安全性 ... 借助计算机辅助药物设计，优化分子结构，尽可能降低脱靶效应，减少对非目标器官的潜在损害。

Viking Therapeutics has announced the start of a Phase II clinical trial for VK2735, an oral tablet aimed at treating metabolic disorders, such as obesity. The VENTURE-Oral Dosing Trial is a ...

The recent data from Novo Nordisk’s Phase 3b trials highlighted the potential advantages of Viking’s VK2735. Pantginis emphasizes that VK2735, a dual GLP-1/GIP receptor agonist, may ...

In contrast, Viking Therapeutics' shares experienced modest gains. Viking's VK2735, a dual GLP-1/GIP receptor agonist, is seen as potentially superior to Novo Nordisk's semaglutide, which only ...

Wall Street is bullish on Viking, but the company still has a lot to prove Viking has a number of different clinical studies ongoing with its lead GLP-1 candidate, VK2735, which is a dual GLP-1 ...

Right now, Novo Nordisk and Eli Lilly are the biggest players in town when it comes to treating diabetes and obesity. Viking Therapeutics has a unique candidate in its pipeline that could disrupt ...

In contrast, Viking Therapeutics' shares experienced modest gains. Viking's VK2735, a dual GLP-1/GIP receptor agonist, is seen as potentially superior to Novo Nordisk's semaglutide, which only targets ...

2025年1月8日，Viking Therapeutics宣布启动口服VK2735在肥胖患者中的2期试验。VK2735是一种靶向胰高血糖素样肽-1（GLP-1）受体和葡萄糖依赖性促胰岛素多肽 ...